Company profile · free preview

Bristol-Myers Squibb

BMY · Updated 10/24/2026

Revenue

$48.2B

Fiscal 2025

Net income

$7.1B

Fiscal 2025

Free cash flow

$12.8B

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$48.2B$48.3B$45.0B$46.2B$46.4B
Net income$7.1B(8.9B)$8.0B$6.3B$7.0B
Diluted EPS—————
Operating cash flow$14.2B$15.2B$13.9B$13.1B$16.2B
Free cash flow$12.8B$13.9B$12.7B$11.9B$15.2B
Cash$10.2B$10.3B$11.5B$9.1B$14.0B
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

8.1%

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $5.9BBar width = share of $72.5B operating cash flow
Operating cash flow$72.5B
Capital expenditure($5.9B)
Free cash flow$66.6B
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

  • 10-K · period 2025-12-312026-02-11EDGAR

Ask anything about Bristol-Myers Squibb's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies